PinnyPeptide

ACE-031 vs GDF-8 95 (Myostatin Inhibitor)

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

ACE-031

Muscle Growth

Soluble myostatin / activin trap — recombinant decoy of the activin IIB receptor.

Peptide B

GDF-8 95 (Myostatin Inhibitor)

Muscle Growth

Short-peptide myostatin inhibitor targeting the GDF-8 / activin RIIB pathway.

Typical vial

1 mg

Typical dose

Per kg dosing mcg

Half-life

~10-15 days (Fc-fusion)

FDA status

Not FDA approved. Clinical development halted in 2011 after …

Typical vial

1 mg

Typical dose

50-200 mcg

Half-life

Variable / poorly characterized for short-peptide formulations

FDA status

Not FDA approved.

ACE-031 effects

  • Inhibits myostatin and related TGF-β superfamily ligands
  • Rapid increases in lean muscle mass in clinical trials
  • Increased thigh muscle volume by MRI
  • Increased serum markers of muscle growth
  • Reduced fat mass in some trial subjects

GDF-8 95 (Myostatin Inhibitor) effects

  • Theoretical inhibition of myostatin signaling
  • Potential muscle hypertrophy via removal of myostatin brake
  • Limited direct evidence for short-peptide formulations in humans
  • Mechanistic rationale supported by pathway biology

ACE-031 side effects

  • Capillary leak (gum bleeds, nosebleeds, telangiectasias) — clinical trial finding
  • Injection-site reactions
  • Headache
  • Potential off-target effects on vasculature and bone
  • Limited long-term safety data

GDF-8 95 (Myostatin Inhibitor) side effects

  • Largely uncharacterized in humans
  • Theoretical: capillary leak if cross-reactivity with other TGF-β ligands occurs
  • Injection-site reactions
  • Possible immunogenicity (anti-drug antibody formation)

ACE-031 dosing ranges

Research / muscle volume increase

0.5-3 mg/kg · IV or SubQ every 2-4 weeks · Per protocol

GDF-8 95 (Myostatin Inhibitor) dosing ranges

Research / muscle hypertrophy

50-200 mcg · Daily or twice-weekly (SubQ) · Per research protocol

Full ACE-031 guide → Full GDF-8 95 (Myostatin Inhibitor) guide →

ACE-031 vs GDF-8 95 (Myostatin Inhibitor) — common questions

What is the difference between ACE-031 and GDF-8 95 (Myostatin Inhibitor)?

ACE-031: Soluble myostatin / activin trap — recombinant decoy of the activin IIB receptor. Typical dose Per kg dosing mcg. GDF-8 95 (Myostatin Inhibitor): Short-peptide myostatin inhibitor targeting the GDF-8 / activin RIIB pathway. Typical dose 50-200 mcg. Both fall under the Muscle Growth category.

Can you stack ACE-031 and GDF-8 95 (Myostatin Inhibitor)?

Stacking ACE-031 with GDF-8 95 (Myostatin Inhibitor) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, ACE-031 or GDF-8 95 (Myostatin Inhibitor)?

ACE-031 is typically dosed: IV or SubQ every 2-4 weeks for Research / muscle volume increase. GDF-8 95 (Myostatin Inhibitor) is typically dosed: Daily or twice-weekly (SubQ) for Research / muscle hypertrophy.

Are ACE-031 and GDF-8 95 (Myostatin Inhibitor) FDA approved?

ACE-031: Not FDA approved. Clinical development halted in 2011 after capillary leak observations. GDF-8 95 (Myostatin Inhibitor): Not FDA approved.

Related peptide comparisons

ace-031 vs b7-33ace-031 vs follistatinace-031 vs igf-1-desace-031 vs igf-1-lr3b7-33 vs gdf-8-95follistatin vs gdf-8-95

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free